ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Field of Research : Immunology
Research Topic : t-cells
Clear All
Filter by Field of Research
Immunology (28)
Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies) (3)
Applied immunology (incl. antibody engineering xenotransplantation and t-cell therapies) (1)
Biological Mathematics (1)
Cellular immunology (1)
Infectious diseases (1)
Innate Immunity (1)
Medical Molecular Engineering of Nucleic Acids and Proteins (1)
Solid Tumours (1)
Stochastic Analysis and Modelling (1)
Tumour Immunology (1)
Filter by Socio-Economic Objective
Cancer and Related Disorders (1)
Expanding Knowledge In the Biological Sciences (1)
Health not elsewhere classified (1)
Human Biological Preventatives (e.g. Vaccines) (1)
Immune System and Allergy (1)
Preventive Medicine (1)
Veterinary Biological Preventatives (e.g. Vaccines) (1)
Filter by Funding Provider
National Health and Medical Research Council (24)
Australian Research Council (4)
Filter by Status
Closed (27)
Active (1)
Filter by Scheme
NHMRC Project Grants (14)
NHMRC Research Fellowships (5)
NHMRC Postgraduate Scholarships (3)
Early Career Fellowships (2)
Linkage Projects (2)
Discovery Early Career Researcher Award (1)
Discovery Projects (1)
Filter by Country
Australia (5)
Filter by Australian State/Territory
VIC (2)
NSW (1)
QLD (1)
SA (1)
  • Researchers (2)
  • Funded Activities (28)
  • Organisations (28)
  • Funded Activity

    Burnet Award - Grant ID:358302

    Funder
    National Health and Medical Research Council
    Funding Amount
    $2,198,356.00
    More information
    Funded Activity

    Research Fellowship - Grant ID:454699

    Funder
    National Health and Medical Research Council
    Funding Amount
    $489,790.00
    Summary
    I am cellular immunologist determining the important host immune cell types and effector molecules that control tumour initiation, growth, and metastasis.
    More information
    Funded Activity

    Chromatin Remodelling And Transcriptional Regulation Of CD8 T Cell Effector Gene Expression

    Funder
    National Health and Medical Research Council
    Funding Amount
    $531,696.00
    Summary
    A major role for cytotoxic, or killer, T cells is the recognition and removal of virus infected or tumor cells from a host. Upon recognition of a target host cell, killer T cells deliver a package of proteins, termed granzymes, that mediate the removal of these virus infected and tumor cells. Naive killer T cells need to be activated to start producing these effector molecules. This proposal plans to examine the factors that regulate both induction and maintanence of cell specific expression of .... A major role for cytotoxic, or killer, T cells is the recognition and removal of virus infected or tumor cells from a host. Upon recognition of a target host cell, killer T cells deliver a package of proteins, termed granzymes, that mediate the removal of these virus infected and tumor cells. Naive killer T cells need to be activated to start producing these effector molecules. This proposal plans to examine the factors that regulate both induction and maintanence of cell specific expression of these effector molecules. We plan to identify the molecular events that occur within a cells genome to turn on granzyme gene expression and how these factors influence subsequent killer T cell function. The conclusions from these studies will enable us to determine why some killer T cell responses are not effective and what can be done to improve killer T cell function. This has implications for the development of novel vaccine strategies designed to induce immunity against both viral and tumour challenges.
    Read more Read less
    More information
    Funded Activity

    Prophlyactic Vaccine For Human Cytomegalovirus

    Funder
    National Health and Medical Research Council
    Funding Amount
    $372,389.00
    Summary
    Human cytomegalovirus (HCMV) is a classic example of a group of herpes viruses, which is found universally throughout all geographic locations and socioeconomic groups, and infects 50% of adults in developed countries. HCMV infection is important to certain high-risk groups. Major areas of concern are: (1) the risk of infection to unborn baby during pregnancy, (2) the risk of infection to people who work with children, and (3) the risk of infection to immunocompromised persons (e.g. organ transp .... Human cytomegalovirus (HCMV) is a classic example of a group of herpes viruses, which is found universally throughout all geographic locations and socioeconomic groups, and infects 50% of adults in developed countries. HCMV infection is important to certain high-risk groups. Major areas of concern are: (1) the risk of infection to unborn baby during pregnancy, (2) the risk of infection to people who work with children, and (3) the risk of infection to immunocompromised persons (e.g. organ transplant patients and HIV-infected individuals). Epidemiological studies have shown that 80%-90% of developing unborn babies who acquire congenital HCMV infection displays a variable pattern of pathological sequelae within the first few years of life that may include hearing loss, vision impairment and mental retardation. There is an increasing argument that a reduction in HCMV load will have a significant effect on the sequelae associated with congenital HCMV infection. Indeed, vaccination provides the most practical modality of achieving such a reduction in HCMV load. To develop such a vaccine, formulation based on viral antigens that activate both protective cellular and humoral responses needs to be tested to assess its immunogenicity. No such vaccine is presently available for HCMV. In this application we have sought to develop a prophylactic vaccine and to test its efficacy in a immunocompetent transgenic mouse model and as well under conditions of immunosuppression (CD4 T cell deficient). The overall strategy is to use this prophylactic vaccine to stimulate the cellular (CD8+ and CD4+ T cells) and humoral responses against multiple HCMV antigens. This vaccine will be based on the novel chimeric polyepitope technology and exploits a novel replication deficient adenovirus expression system which has recently been approved for human use.
    Read more Read less
    More information
    Funded Activity

    A T Cell-Specific GR Promoter Determines Responsiveness To Glucocorticoids In Different Immune Compartments

    Funder
    National Health and Medical Research Council
    Funding Amount
    $417,500.00
    Summary
    Synthetic glucocorticoids, such as dexamethasone and prednisolone, are commonly used as potent anti-inflammatory steroid drug during the treatment of major human trauma and cancer. A side-effect of these very high steroid doses is a major down-regulation of the immune system, particularly massive death of important immune cells called T-cells, which can have a major impact on patient recovery and potential mortality. These T cells are particularly sensitive to glucocorticoid-induced cell death a .... Synthetic glucocorticoids, such as dexamethasone and prednisolone, are commonly used as potent anti-inflammatory steroid drug during the treatment of major human trauma and cancer. A side-effect of these very high steroid doses is a major down-regulation of the immune system, particularly massive death of important immune cells called T-cells, which can have a major impact on patient recovery and potential mortality. These T cells are particularly sensitive to glucocorticoid-induced cell death and have very high levels of receptors for these steroids called glucocorticoid receptors (GRs). We have discovered a unique GR gene promoter (designated 1A) that is active in T cells. Very little is known about how this gene promoter is regulated. This promoter may be a useful therapeutic target to block T cell death (caused by steroids) during recovery from injury, infection and cancer. Separation of anti-inflammatory and side-effects such as high T-cell death or blockade of these effects on T cells would have a major impact on patient immune status and recovery, and reduce the incidence of debilitating side-effects. Therapeutic down-regulation of this T cell-specific GR gene promoter could lead to targeted blockade of steroid-induced T cell death and help maintain a strong immune system. This application brings together a unique team of investigators (CIs) that have a strong history of collaboration in this area with recent publications in very high ranking international journals. The CIs bring a multi-disciplined approach combining endocrinology, molecular biology and cellular immunology to determine the underlying mechanisms of steroid actions and their effects on immune function. Both Dr Cole (CIA) and Dr Godfrey (CIB) have excellent track records in this area.
    Read more Read less
    More information
    Funded Activity

    Factors Involved In The Development And Homeostasis Of CD4 Memory T Cells

    Funder
    National Health and Medical Research Council
    Funding Amount
    $306,863.00
    More information
    Funded Activity

    Research Fellowship - Grant ID:358303

    Funder
    National Health and Medical Research Council
    Funding Amount
    $651,750.00
    More information
    Funded Activity

    Structural Basis Of Influenza A Virus-specific CD8+ T Cell Receptor Diversity

    Funder
    National Health and Medical Research Council
    Funding Amount
    $469,500.00
    Summary
    Viral infection results in the activation and proliferation of virus-specific T cells that mediate clearance of virally infected cells. Recognition of virally infected cells is meditated by presentation of peptide fragments complexed to Major histocompatibility complex (MHC) class I glycoproteins. Virus-specific T cells recognise these viral protein fragments via a specific receptor expressed at the T cell surface. This proposal plans to examine the structural factors that determine influenza-sp .... Viral infection results in the activation and proliferation of virus-specific T cells that mediate clearance of virally infected cells. Recognition of virally infected cells is meditated by presentation of peptide fragments complexed to Major histocompatibility complex (MHC) class I glycoproteins. Virus-specific T cells recognise these viral protein fragments via a specific receptor expressed at the T cell surface. This proposal plans to examine the structural factors that determine influenza-specific T cell receptor recognition. From these studies, we plan to determine how these structural factors can influence the diversity of virus-specific T cells that are generated after viral infection. The conclusions from these studies will enable us to determine why some virus-specific T cell responses are not diverse and what are the consequences for virus-specific T cell immunity. This has implications for the development of novel vaccine strategies designed to induce immunity against both viral and tumour challenge.
    Read more Read less
    More information
    Funded Activity

    CD4+ T Cell Programming By Early Life And Neonatal Infection

    Funder
    National Health and Medical Research Council
    Funding Amount
    $21,866.00
    More information
    Funded Activity

    Research Fellowship - Grant ID:403970

    Funder
    National Health and Medical Research Council
    Funding Amount
    $664,574.00
    More information

    Showing 1-10 of 28 Funded Activites

    • 1
    • 2
    • 3
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback